Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2012 / Cilt: 38 - Sayı: 1

Renal hücreli karsinomda karbonik anhidraz 9 ve HIF-1α’nın prognostik değeri

Prognostic value of carbonic anhydrase IX and HIF-1α in renal cell carcinoma

Pages
1–7
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: We noted that there was no relationship between CA9 and HIF-1 α expression with other prognostic clinicopathologic features.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we evaluated the prognostic value of carbonic anhydrase IX (CA9) and HIF-1 α and their relations with anatomic, histopathologic and clinic prognostic factors.
📊
Key Findings & Data:Materials and Methods: Immunohistochemical analysis was performed on paraffin-embedded specimens from 39 patients treated with a nephrectomy for renal cell carcinoma.
💡
Conclusion & Impact:Conclusions: We noted that there was no relationship between CA9 and HIF-1 α expression with other prognostic clinicopathologic features.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we evaluated the prognostic value of carbonic anhydrase IX (CA9) and HIF-1 &#945; and their relations with anatomic, histopathologic and clinic prognostic factors. Materials and Methods: Immunohistochemical analysis was performed on paraffin-embedded specimens from 39 patients treated with a nephrectomy for renal cell carcinoma. The immunoreactivity levels of CA9 and HIF-1 &#945; were classified into four groups: 0%, 1-25%, 26-50%, >50% for CA9; and &#8804;1-10%, 11-50%, 51-80%, >80% for HIF-1&#945;. The CA9 and HIF-1&#945; stains were compared with the patient’s age, sex, tumor volume, recurrence status, T stage and Fuhrman grade. Results: The age distribution of all patients with clear cell renal cell carcinoma (RCC) was as follows: 23 (59%) were older than 50, and 16 (41%) were younger. Twenty-eight patients (71.8%) were male, and 11 (28.2%) were female. Among these patients, 34 (87.2%) survived, and 5 (12.8%) died because of RCC. Seven (17.9%) patients had a recurrence after undergoing a nephrectomy. Twenty-four (61.5%) patients were classified as stage T1 and 15 (38.2%) as stage T2. Thirty-three (84.6%) patients were classified as Fuhrman grade 2 and six (15.4%) patients as Fuhrman grade 3. Although there were different degrees of staining, immunohistochemical staining was positive in all pathological samples for either CA9 or HIF-1&#945;(7 1-25%, 15 26-50%, 17 >%50 for CA9; 11 <10%, 10 10-50%, 14 50-80%, 4 >80% for HIF-1&#945; ). Among the CA9 immunoreactive-positive patients, the number of male patients was statistically higher in the 1-25% group than the 26-50% and >50% groups (p=0.019). Among HIF-1&#945; immunoreactive-positive patients, the &#8804;%10 group had a statistically lower number of tumors sized >4 cm than the other groups (p=0.01). Conclusions: We noted that there was no relationship between CA9 and HIF-1 &#945; expression with other prognostic clinicopathologic features.

Özet

Amaç: Bu çalışmada, Karbonik anhidraz-IX (CA9) ve hipoksi indüklenebilir faktör 1- α (HIF-1 α )’nın prog - nostik değeri ile anatomik, histopatolojik ve klinik prognostik faktörlerle arasındaki ilişkiyi değerlendirdik. Gereç ve yöntem: Böbrek kanseri tanısı ile radikal nefrektomi yapılmış olan ve patolojisi berrak hücrel renal kanser gelen 39 hastanın parafine gömülü doku örneklerinden immünohistokimyasal analiz yapıl - dı. CA9 ve HIF-1 α immünoreaktivite düzeyleri dört grupta sınıflandırıldı: CA9 için %0, %1-25, %26-50, >%50; HIF-1 α için ≤%1-10, %11-50, %51-80, >%80. CA9 ve HIF-1 α boyanmaları hasta yaşı, cinsiyet, tümör hacmi ve nüks durumu, T evresi ve Fuhrman derecesi ile karşılaştırıldı. Bulgular: Berrak hücreli böbrek kanserli tüm hastaların yaş dağılımında 23’ü (%59) 50 yaşından büyük; 16’sı (%41) 50 yaşından küçüktü. Yirmi-sekiz (%71.8) hasta erkek ve 11 (%28.2) hasta kadındı. Bu hastaların 34’ü (%87.2) hayatta; 5’i (%12.8) böbrek hücreli kanser (BHK) nedeniyle exitus idi. 7 (%17.9) hastada nef - rektomi sonrası rekürrens olmuştu. Yirmi-dört (%61.5) hasta T1; 15 (%38.2) hasta T2 evreydi. 33 (%84.6) hasta Fuhrman derece 2; 6 (%15.4) hasta Fuhrman derece 3’tü. Boyanma dereceleri farklı olduysa da, tüm patolojik preparatlarda hem CA9 hem de HIF-1α için immünohistokimyasal boyanma pozitifti (7 %1-25, 15 %26-50, 17 > %50 CA9 için; 11 %80 HIF-1α için). CA9 pozitif hastalar arasında, %1-25’lik gruptaki erkek hasta sayısı %26-50 ve >%50’lik gruptan istatistiksel olarak daha fazlaydı (p=0.019). Tümör hacmine göre, HIF-1α immunoreaktivitesi pozitif hastalarda, İmmunoreaktivitesi ≤%10 olan grupta >4 cm tümör bulunma oranı istatistiksel olarak diğer gruplardan anlamlı olarak azdı (p=0.01). Sonuç: CA9 ve HIF-1α ekspresyonunun diğer prognostik klinikopatolojik özelliklerle arasında bir ilişki olmadığını saptadık.

🔖

Cite This Article

GÜNAYDIN, B., YILDIRIM, A., ZEMHERİ, I. E., ÖZKANLI, S. Ş., GÖÇER, S., KESKİN, S. K., BAŞOK, E. K. (2012). Renal hücreli karsinomda karbonik anhidraz 9 ve HIF-1α’nın prognostik değeri. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 38 - Sayı: 1, 1–7. https://ajindex.com/articles/328647

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001
  2. [CrossRef] 2.Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997
  3. Ivanov S, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel- Lindau transgenes. Proc Natl Acad Sci USA 1998
  4. 12596-601. [CrossRef] 4.Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003
  5. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995
  6. [CrossRef] 6.Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005
  7. 66(5 Suppl): 1-9. [CrossRef] 7.Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999
  8. [CrossRef] 8.Saarnio J, Parkkila S, Parkkila AK, Pastorekova S, Haukipuro K, Pastorek J, et al. Transmembrane carbonic anhydrase, MN/ CA IX, is a potential biomarker for biliary tumours. J Hepatol 2001
  9. [CrossRef] 9.Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/ CA IX, with p otential value as a marker of cell proliferation. Am J Pathol 1998
  10. [CrossRef] 10.Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007
  11. [CrossRef] 11.Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007
  12. [CrossRef] 12.Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, et al. Low CA9 expression and absence of VHL gene mutation are ass